title: Initiation of glucose-based peritoneal dialysis is associated with increased prevalence of metabolic syndrome in non-diabetic patients with end-stage renal disease.
abstract: BACKGROUND
  Glucose-based peritoneal dialysis (PD) is the original PD form. However, glucose uptake from the peritoneal cavity may contribute to dysmetabolism.
  
  
  METHODS
  We retrospectively assessed metabolic syndrome (MS) and its components in 195 non-diabetic incident PD patients at baseline and after 34.3 (20.5-60.0) months of PD. MS was defined according to the Adult Treatment Panel III criteria.
  
  
  RESULTS
  While 22.1% of the patients met MS criteria at baseline, 69.2% (p < 0.01) exhibited MS during PD. MS burden increased significantly after PD (p < 0.01). The disorder BMI and lipids, and MS components number, correlated with peritoneal glucose exposure and PD duration (p < 0.05). In Cox analysis, age, BMI, triglyceride, C-reactive protein (CRP) and glucose exposure were all independently associated with MS development.
  
  
  CONCLUSIONS
  PD commencement in end-stage renal disease patients was associated with an increased MS prevalence. High glucose exposure and long PD duration were associated with MS existence, along with old age, high BMI, triglyceride and CRP.
authors.affiliation: Renal Division, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Center for Peritoneal Dialysis Research, Shanghai, PR China.
authors.forename: Na
authors.initials: N
authors.lastname: Jiang
authors.forename: Jiaqi
authors.initials: J
authors.lastname: Qian
authors.forename: Aiwu
authors.initials: A
authors.lastname: Lin
authors.forename: Bengt
authors.initials: B
authors.lastname: Lindholm
authors.forename: Jonas
authors.initials: J
authors.lastname: Axelsson
authors.forename: Qiang
authors.initials: Q
authors.lastname: Yao
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis; D015314:Dialysis Solutions / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005947:Glucose / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000139:chemically induced*; D008875:Middle Aged; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D012189:Retrospective Studies; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D015314:Dialysis Solutions; D014280:Triglycerides; D002097:C-Reactive Protein; D005947:Glucose